0 patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
This portfolio holds none of the 4 US patents in force on its record. from the record
Of the 4 now held by other companies, 4 name Pierre Fabre Médicament as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2013 to 2042.
US 8,729,043
Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products
Feb 5, 2027
US 8,388,958
Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products
Jul 18, 2029
US 11,814,433
Combination of Anti-Hgfr Antibody and Hegfr for the Treatment of a Tumor And/Or Metastasis
Nov 20, 2039
20192025203120372042
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Jul 2029 · High confidence
The most cited patent in this portfolio, cited by 22 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2029.
now held by Pierre Fabre Médicament
Also notable
Ends Nov 2039 · High confidence
Granted 2023. Computed term ends 2039.
now held by Pierre Fabre Médicament
Also notable
Ends Feb 2042 · High confidence
Granted 2025. Too new for citation comparison; protection runs to 2042.
now held by Pierre Fabre Médicament
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Also on record: 4 patents in force now held by others. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.